爱达荷州 的 肺癌 临床试验
爱达荷州 有 11 项针对 肺癌 的研究正在招募参与者。
爱达荷州 的城市
官方研究文本（英文）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- 以及另外 3 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- 以及另外 9 项
招募中观察性研究欢迎健康志愿者
40 至 75 岁 · 所有性别 · 更新于 2026年10月2日 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- 以及另外 3 项
招募中3 期
70 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- 以及另外 8 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT04181060Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Saint Luke's Cancer Institute - Boise, Boise
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- Saint Luke's Cancer Institute - Fruitland, Fruitland
- 以及另外 5 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06498635A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- St. Luke's Cancer Institute: Boise, Boise
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT07063745A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- St. Luke's Cancer Institute, Boise
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月8日 · NCT06793215Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- 以及另外 3 项
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年6月3日 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- 以及另外 3 项
招募中2 期
18 Minutes · 所有性别 · 更新于 2026年5月5日 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- 以及另外 8 项
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年5月5日 · NCT06616584SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Boise
招募中观察性研究
所有年龄段 · 所有性别 · 更新于 2025年10月28日 · NCT03452774数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。